← Oestriol

Patient counseling sheet

Print-ready and generated without storing patient details.

AfyaIndex · counseling handout

Oestriol

Therapeutic agent (verify pharmacological class)

Prepared 24 Sep 2026

What it is used for

Moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, palliation in breast cancer (women and men with metastatic disease, prevention of osteoporosis, advanced androgen-dependent carcinoma of the prostate, for palliation only

Warnings

Physical/history examination before initiating oestrogen therapy should be done; fluid retention; women with narrow vagina; uterovaginal prolapse; treatment unresponsive infection; Cushing syndrome; BP monitor; 4 weeks before surgery; history of endometriosis.

Possible side effects

Changes in menstrual flow; break through bleeding; dysmenorrhoea; amenorrhoea during and after treatment; GI disturbances; allergic reactions; visual disturbances; mental depression; convulsion; fluid retention; aggravation of existing hypertension; tenderness and enlargement of the breasts; headache; pre-mature closure of epiphysis; aggravation of endometriosis.

Storage

Store as labelled. Keep out of reach of children.

No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.

AfyaIndex dataset coverage